# US 2026/0097126 A1 · Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097126 A1
- Document ID: US20260097126A1
- Status: Published application
- Kind: A1
- Application number: 18/995,773
- Filed: 2023-07-18
- Published: 2026-04-09
- Earliest claimed: 2022-07-20
- Assignees: Viking Therapeutics, Inc.
- Applicants: Viking Therapeutics, Inc.
- Inventors: Brian Lian; Geoffrey E. Barker; Maureen Barnes; Brahmachary Enugurthi; Jake Gonzalez
- Web page: https://patentgrep.com/patent/US20260097126A1

## CPC

- A61K 47/548: {Phosphates or phosphonates, e.g. bone-seeking (phospholipids A61K47/544)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/26: Glucagons
- A61K 47/02: Inorganic compounds
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 13/12: of the kidneys
- C07K 19/00: Hybrid peptides {, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein are formulations of small molecule GIP/GLP-1 dual receptor agonists and uses thereof.

## Claims

### Claim 1

A pharmaceutical composition, comprising:
one or more non-aqueous solvent or a solubility enhancer, comprising less than 20% by weight of the pharmaceutical composition; and
a compound having the structure of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Aib is 2-aminoisobutyric acid;
each instance of J1, J2, and J3 is independently an amino acid selected from Aib, a naturally occurring amino acid, and an unnatural amino acid;
each instance of J4, J5, J6, J7, J8, J9, J10, and J11 is independently a naturally occurring amino acid or an unnatural amino acid;
each of n1, n2, n3, n4, n5, n6, n7, and n8 is independently 0 or 1, provided that the sum n1+n2+n3+n4+n5+n6+n7+n8 is 4;
R1 is selected from the group consisting of —C(═O)(OZ1), —P(═O)(X)(Y) and a 5-10 membered heteroaryl containing 1-2 heteroatoms selected from N, O and S, the heteroaryl optionally substituted with 1-2 R7;
R2 is selected from the group consisting of —C(═O)(OZ2), —P(═O)(X)(Y) and a 5-10 membered heteroaryl containing 1-2 heteroatoms selected from N, O and S, the heteroaryl optionally substituted with 1-2 R7;
each R7 is independently selected from the group consisting of halogen, C1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy, OR5, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl and 5-10 membered heterocyclyl;
X and Y each are independently selected from the group consisting of —OR4, NR5R6, C1-6 alkyl and haloC1-6 alkyl;
each R4 is independently selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C6-10 aryl and C7-11 arylalkyl;
each R5 is independently hydrogen or C1-6 alkyl;
each R6 is independently hydrogen or C1-6 alkyl; and
Z1 and Z2 each are independently selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl; and
wherein the compound is not

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein each instance of J1, J2, and J3 is independently an amino acid selected from Aib and a naturally occurring amino acid.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein each instance of J1, J2, and J3 is independently an amino acid selected from Aib, A, F, N, R, and Q.

### Claim at position 5

5-6. (canceled)

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein J2 of the compound of Formula I is N or Q.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein J3 of the compound of Formula I is A or R.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein each instance of J4, J5, J6, and J7 of the compound of Formula I is independently an amino acid selected from A, I, K, R, Q, S, T, and V.

### Claim at position 11

12-13. (canceled)

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein J5 of the compound of Formula I is I, T, or V.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein J6 of the compound of Formula I is A or S.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

The pharmaceutical composition of claim 1, wherein J7 of the compound of Formula I is Q.

### Claim 19 (depends on 1)

The pharmaceutical composition of claim 1, wherein each instance of J8, J9, J10, and J11 of the compound of Formula I is independently an amino acid selected from A, I, and Q.

### Claim at position 18

20-23. (canceled)

### Claim 24 (depends on 1)

The pharmaceutical composition of claim 1, wherein
J1 of the compound of Formula I is selected from Aib or F;
J2 of the compound of Formula I is selected from Q or N;
J3 of the compound of Formula I is selected from A or R;
U1 of the compound of Formula I is selected from -K-V-A-, -K-I-A-Q-, -K-T-A-Q-, —K-T-S-Q-, -K-V-A-Q-, -R-I-A-Q-, or is absent; and
U2 of the compound of Formula I is selected from -Q-, -I-A-Q-Q-, or is absent.

### Claim 25 (depends on 1)

The pharmaceutical composition of claim 1, wherein each instance of n1, n2, n3, and n4 of the compound of Formula I is zero; or wherein each instance of n4, n6, n7, and n8 of the compound of Formula I is zero; or wherein each instance of n5, n6, n7, and n8 of the compound of Formula I is zero.

### Claim at position 21

26-27. (canceled)

### Claim 28 (depends on 1)

The pharmaceutical composition of claim 1, wherein when Z1 and Z2 are both present, at least one of Z1 and Z2 of the compound of Formula I is not hydrogen.

### Claim 29 (depends on 1)

The pharmaceutical composition of claim 1, wherein the compound has the structure of formula I-a:
or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 29)

The pharmaceutical composition of claim 29, wherein Z1 is selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl; and X and Y each are —OR4.

### Claim at position 25

31-32. (canceled)

### Claim 33 (depends on 30)

The pharmaceutical composition of claim 30, wherein Z1 of the compound of Formula I-a is hydrogen and each R4 of the compound of Formula I-a is hydrogen.

### Claim 34 (depends on 1)

The pharmaceutical composition of claim 1, wherein the compound has the structure of formula I-b:
or a pharmaceutically acceptable salt thereof.

### Claim 35 (depends on 34)

The pharmaceutical composition of claim 34, wherein each R4 of the compound of Formula I-b is independently selected from the group consisting of hydrogen, C6-10 aryl and C7-11 arylalkyl.

### Claim 36

(canceled)

### Claim 37 (depends on 1)

The pharmaceutical composition of claim 1, wherein the compound has the structure selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim 38

A pharmaceutical composition, comprising:
one or more non-aqueous solvent or a solubility enhancer, comprising less than 20% by weight of the pharmaceutical composition; and a compound having the structure of formula II:
or a pharmaceutically acceptable salt thereof, wherein:
“*” indicates a chiral carbon with “S” configuration or “R” configuration;
R1 is selected from the group consisting of —C(═O)(OZ1), —P(═O)(X)(Y) and a 5-10 membered heteroaryl containing 1-2 heteroatoms selected from N, O and S optionally substituted with 1-2 R7;
R2 is selected from the group consisting of —C(═O)(OZ2), —P(═O)(X)(Y) and a 5-10 membered heteroaryl containing 1-2 heteroatoms selected from N, O and S optionally substituted with 1-2 R7;
each R7 is independently selected from the group consisting of halogen, C1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy, OR5, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl and 5-10 membered heterocyclyl;
X and Y each are independently selected from the group consisting of —OR4, NR5R6, C1-6 alkyl and haloC1-6 alkyl;
each R4 is independently selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C6-10 aryl and C6-10 arylalkyl;
each R5 is independently hydrogen or C1-6 alkyl;
each R6 is independently hydrogen or C1-6 alkyl; and
Z1 and Z2 each are independently selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl,
wherein when Z1 and Z2 are both present, at least one of Z1 and Z2 is not hydrogen.

### Claim 39 (depends on 38)

The pharmaceutical composition of claim 38, having the structure of formula II-a:
or a pharmaceutically acceptable salt thereof.

### Claim 40 (depends on 39)

The pharmaceutical composition of claim 39, wherein Z1 is selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl; and X and Y each are —OR4.

### Claim at position 34

41-42. (canceled)

### Claim 43 (depends on 40)

The pharmaceutical composition of claim 40, wherein each R4 is hydrogen.

### Claim 44

(canceled)

### Claim 45 (depends on 38)

The pharmaceutical composition of claim 38, having the structure of formula II-b:
or a pharmaceutically acceptable salt thereof.

### Claim 46 (depends on 45)

The pharmaceutical composition of claim 45, wherein Z2 is selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl; and X and Y each are —OR4.

### Claim at position 39

47-48. (canceled)

### Claim 49 (depends on 46)

The pharmaceutical composition of claim 46, wherein Z2 is hydrogen and each R4 is hydrogen.

### Claim 50

(canceled)

### Claim 51 (depends on 38)

The pharmaceutical composition of claim 38, having the structure of formula II-c:
or a pharmaceutically acceptable salt thereof.

### Claim 52 (depends on 51)

The pharmaceutical composition of claim 51, wherein X and Y each are —OR4.

### Claim 53

(canceled)

### Claim 54 (depends on 52)

The pharmaceutical composition of claim 52, wherein each R4 is hydrogen.

### Claim 55

A pharmaceutical composition comprising:
one or more non-aqueous solvent or a solubility enhancer, comprising less than 20% by weight of the pharmaceutical composition; and a compound having the structure selected from the group consisting of:
and pharmaceutically acceptable salts thereof.

### Claim at position 47

56-57. (canceled)

### Claim 58 (depends on 1)

The pharmaceutical composition of claim 1, wherein the one or more non-aqueous solvent or a solubility enhancer comprises less than 10% by weight of the composition.

### Claim 59

(canceled)

### Claim 60 (depends on 1)

The pharmaceutical composition of claim 1, wherein the one or more non-aqueous solvent or a solubility enhancer comprises propylene glycol.

### Claim 61 (depends on 60)

The pharmaceutical composition of claim 60, wherein the propylene glycol is present at a weight percentage of equal to or less than about 10%.

### Claim at position 52

62-64. (canceled)

### Claim 65 (depends on 1)

The pharmaceutical composition of claim 1, wherein the one or more non-aqueous solvent or a solubility enhancer comprises a polysorbate.

### Claim 66 (depends on 65)

The pharmaceutical composition of claim 65, wherein the polysorbate is present at a weight percentage of approximately 0.001% to approximately 0.1%.

### Claim 67

(canceled)

### Claim 68 (depends on 65)

The pharmaceutical composition of claim 65, wherein the polysorbate is polysorbate 20 or polysorbate 80.

### Claim 69

(canceled)

### Claim 70 (depends on 1)

The pharmaceutical composition of claim 1, wherein the one or more non-aqueous solvent or a solubility enhancer comprises glycerol.

### Claim 71 (depends on 70)

The pharmaceutical composition of claim 70, wherein the glycerol is present at a weight percentage of approximately 0.5% to approximately 5%.

### Claim at position 60

72-73. (canceled)

### Claim 74 (depends on 1)

The pharmaceutical composition of claim 1, wherein the one or more non-aqueous solvent or a solubility enhancer comprises phenol.

### Claim 75 (depends on 74)

The pharmaceutical composition of claim 74, wherein the phenol is present at a weight percentage of approximately 0.1% to approximately 1%.

### Claim 76

(canceled)

### Claim 77 (depends on 1)

The pharmaceutical composition of claim 1, comprising approximately 0.1% to approximately 5% propylene glycol by weight and approximately 0.1% to approximately 1% phenol by weight.

### Claim 78 (depends on 77)

The pharmaceutical composition of claim 77, comprising approximately 0.001% to approximately 0.01% polysorbate 80 by weight.

### Claim 79

A pharmaceutical composition, comprising:
lactose; and
a therapeutically effective amount of a compound having the structure of formula II, or a pharmaceutically acceptable salt thereof:
wherein:
“*” indicates a chiral carbon with “S” configuration or “R” configuration;
R1 is selected from the group consisting of —C(═O)(OZ1), —P(═O)(X)(Y) and a 5-10 membered heteroaryl containing 1-2 heteroatoms selected from N, O and S optionally substituted with 1-2 R7;
R2 is selected from the group consisting of —C(═O)(OZ2), —P(═O)(X)(Y) and a 5-10 membered heteroaryl containing 1-2 heteroatoms selected from N, O and S optionally substituted with 1-2 R7;
each R7 is independently selected from the group consisting of halogen, C1-6 alkyl, haloC1-6 alkyl, haloC1-6 alkoxy, OR5, C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl and 5-10 membered heterocyclyl;
X and Y each are independently selected from the group consisting of —OR4, NR5R6, C1-6 alkyl and haloC1-6 alkyl;
each R4 is independently selected from the group consisting of hydrogen, C1-6 alkyl,
haloC1-6 alkyl, C6-10 aryl and C6-10 arylalkyl;
each R5 is independently hydrogen or C1-6 alkyl;
each R6 is independently hydrogen or C1-6 alkyl; and
Z1 and Z2 each are independently selected from the group consisting of hydrogen, C1-6 alkyl, haloC1-6 alkyl, C3-10 cycloalkyl and C6-10 aryl,
wherein when Z1 and Z2 are both present, at least one of Z1 and Z2 is not hydrogen.

### Claim 80 (depends on 79)

The pharmaceutical composition of claim 79, wherein the lactose is present as lactose monohydrate at a weight percentage of approximately 2% to approximately 10%.

### Claim at position 68

81-82. (canceled)

### Claim 83 (depends on 1)

The pharmaceutical composition of claim 1, comprising a pharmaceutically acceptable aqueous carrier, wherein the aqueous carrier is water or saline.

### Claim 84

(canceled)

### Claim 85 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition comprises a buffer, wherein the buffer comprises sodium citrate, phosphate disodium, L-histidine, methionine, tartrate, citrate, acetate, 2-(N-morpholino)ethanesulfonic acid (MES), piperazine-N,N′-bis(2-ethanesulfonic acid (PIPES), 3-(N-morpholino)propanesulfonic acid (MOPS), 2-[[1,3-dihydroxy-2-(hydroxymethyl) propan-2-yl]amino]ethanesulfonic acid (TES), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-[N-tris(hydroxymethyl)methylamino]-2-hydroxypropanesulfonic acid (TAPSO), N-[tris(hydroxymethyl)methyl]glycine (Tricine), tris(hydroxymethyl)aminomethane (Tris), 2-(bis(2-hydroxyethyl)amino)acetic acid (Bicine), tris(hydroxymethyl)methylamino]propanesulfonic acid (TAPS), N-cyclohexyl-2-aminoethanesulfonic acid (CHES), phosphate, borate, or any combination of the foregoing.

### Claim at position 72

86-90. (canceled)

### Claim 91 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition has a pH from about 2 to 12.

### Claim at position 74

92-93. (canceled)

### Claim 94 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition is configured for subcutaneous administration.

### Claim at position 76

95-105. (canceled)

### Claim 106 (depends on 1)

A method of preventing, treating, or ameliorating one or more fatty liver diseases in a subject, comprising administering a pharmaceutical composition of claim 1 to a subject in need thereof, wherein the fatty liver disease is selected from the group consisting of steatosis, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease.

### Claim at position 78

107-111. (canceled)

### Claim 112 (depends on 1)

A method of preventing, treating, or ameliorating one or disease or disorders in a subject, comprising administering a pharmaceutical composition of claim 1 to a subject in need thereof, wherein the disease or disorder is liver fibrosis, renal fibrosis, biliary fibrosis, pancreatic fibrosis, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, chronic kidney disease, diabetic kidney disease, primary sclerosing cholangitis, primary biliary cirrhosis, or idiopathic fibrosis.

### Claim 113

(canceled)

### Claim 114 (depends on 106)

The method of claim 106, wherein the route of administration is subcutaneous.

### Claim 115 (depends on 1)

A method of preventing, treating, or ameliorating one or disease or disorders in a subject, comprising administering a pharmaceutical composition of claim 1 to a subject in need thereof, wherein the disease or disorder is atherosclerosis, diabetes, hyperglycemic diabetes, type 2 diabetes mellitus, dyslipidemia, hypercholesterolemia, hyperlipidemia, hypertension, hypoglycemia, obesity, or prader-willi syndrome.
